Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure.
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Review of heart failure medications and microbiome insights for individualized treatment strategies
Could gut bacteria help tailor heart failure treatment for better results?
This narrative review examines heart failure management involving digoxin, angiotensin receptor-neprilysin inhibitors, ACE inhibitors, ARBs,…
Gut bacteria might help tailor heart failure treatments to work better for specific people by influencing how standard medicines affect the …